GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SpectraCure AB (OSTO:SPEC) » Definitions » Cyclically Adjusted Price-to-FCF

SpectraCure AB (OSTO:SPEC) Cyclically Adjusted Price-to-FCF : (As of Jun. 28, 2025)


View and export this data going back to 2015. Start your Free Trial

What is SpectraCure AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


SpectraCure AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for SpectraCure AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpectraCure AB Cyclically Adjusted Price-to-FCF Chart

SpectraCure AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SpectraCure AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SpectraCure AB's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, SpectraCure AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SpectraCure AB's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SpectraCure AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where SpectraCure AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

SpectraCure AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

SpectraCure AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, SpectraCure AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.042/132.8245*132.8245
=-0.042

Current CPI (Mar. 2025) = 132.8245.

SpectraCure AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.000 99.995 0.000
201509 0.000 100.228 0.000
201512 0.000 100.276 0.000
201603 -0.032 100.751 -0.042
201606 -0.039 101.019 -0.051
201609 -0.022 101.138 -0.029
201612 -0.210 102.022 -0.273
201703 0.080 102.022 0.104
201706 -0.021 102.752 -0.027
201709 -0.016 103.279 -0.021
201712 -0.029 103.793 -0.037
201803 -0.002 103.962 -0.003
201806 -0.040 104.875 -0.051
201809 -0.030 105.679 -0.038
201812 -0.038 105.912 -0.048
201903 -0.015 105.886 -0.019
201906 -0.096 106.742 -0.119
201909 -0.031 107.214 -0.038
201912 -0.046 107.766 -0.057
202003 -0.015 106.563 -0.019
202006 -0.041 107.498 -0.051
202009 -0.026 107.635 -0.032
202012 -0.006 108.296 -0.007
202103 -0.017 108.360 -0.021
202106 -0.053 108.928 -0.065
202109 -0.019 110.338 -0.023
202112 -0.028 112.486 -0.033
202203 -0.032 114.825 -0.037
202206 -0.047 118.384 -0.053
202209 -0.033 122.296 -0.036
202212 -0.032 126.365 -0.034
202303 -0.048 127.042 -0.050
202306 -0.049 129.407 -0.050
202309 -0.028 130.224 -0.029
202312 -0.027 131.912 -0.027
202403 -0.038 132.205 -0.038
202406 -0.050 132.716 -0.050
202409 -0.028 132.304 -0.028
202412 -0.044 132.987 -0.044
202503 -0.042 132.825 -0.042

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SpectraCure AB  (OSTO:SPEC) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


SpectraCure AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of SpectraCure AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


SpectraCure AB Business Description

Traded in Other Exchanges
Address
Magistratsvagen 10, Lund, SWE, 22643
SpectraCure AB develops treatment planning and laser light dose management for cancer treatment. The Company has developed its software IDOSE, and medical laser devices for the treatment.